CAR-T Cell Therapy: From the Shop to Cancer Therapy

Ashanti Concepción Uscanga-Palomeque; Ana Karina Chávez-Escamilla; Cynthia Aracely Alvizo-Báez; Santiago Saavedra-Alonso; Luis Daniel Terrazas-Armendáriz; Reyes S. Tamez-Guerra; Cristina Rodríguez-Padilla; Juan Manuel Alcocer-González

doi:10.3390/ijms242115688

CAR-T Cell Therapy: From the Shop to Cancer Therapy

Ashanti Concepción Uscanga-Palomeque^*, Ana Karina Chávez-Escamilla, Cynthia Aracely Alvizo-Báez, Santiago Saavedra-Alonso, Luis Daniel Terrazas-Armendáriz, Reyes S. Tamez-Guerra, Cristina Rodríguez-Padilla, Juan Manuel Alcocer-González^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

35 Citations (Scopus)

Abstract

Cancer is a worldwide health problem. Nevertheless, new technologies in the immunotherapy field have emerged. Chimeric antigen receptor (CAR) technology is a novel biological form to treat cancer; CAR-T cell genetic engineering has positively revolutionized cancer immunotherapy. In this paper, we review the latest developments in CAR-T in cancer treatment. We present the structure of the different generations and variants of CAR-T cells including TRUCK (T cells redirected for universal cytokine killing. We explain the approaches of the CAR-T cells manufactured ex vivo and in vivo. Moreover, we describe the limitations and areas of opportunity for this immunotherapy and the current challenges of treating hematological and solid cancer using CAR-T technology as well as its constraints and engineering approaches. We summarize other immune cells that have been using CAR technology, such as natural killer (NK), macrophages (M), and dendritic cells (DC). We conclude that CAR-T cells have the potential to treat not only cancer but other chronic diseases.

Original language	English
Article number	15688
Journal	International Journal of Molecular Sciences
Volume	24
Issue number	21
DOIs	https://doi.org/10.3390/ijms242115688 https://doi.org/10.3390/ijms242115688
Publication status	Published - Nov 2023
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2023 by the authors.

All Science Journal Classification (ASJC) codes

Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Cite this

Uscanga-Palomeque, A. C., Chávez-Escamilla, A. K., Alvizo-Báez, C. A., Saavedra-Alonso, S., Terrazas-Armendáriz, L. D., Tamez-Guerra, R. S., Rodríguez-Padilla, C., & Alcocer-González, J. M. (2023). CAR-T Cell Therapy: From the Shop to Cancer Therapy. International Journal of Molecular Sciences, 24(21), Article 15688. https://doi.org/10.3390/ijms242115688, https://doi.org/10.3390/ijms242115688

@article{229b45d87e954bb8b479e480c2c7cd3b,

title = "CAR-T Cell Therapy: From the Shop to Cancer Therapy",

abstract = "Cancer is a worldwide health problem. Nevertheless, new technologies in the immunotherapy field have emerged. Chimeric antigen receptor (CAR) technology is a novel biological form to treat cancer; CAR-T cell genetic engineering has positively revolutionized cancer immunotherapy. In this paper, we review the latest developments in CAR-T in cancer treatment. We present the structure of the different generations and variants of CAR-T cells including TRUCK (T cells redirected for universal cytokine killing. We explain the approaches of the CAR-T cells manufactured ex vivo and in vivo. Moreover, we describe the limitations and areas of opportunity for this immunotherapy and the current challenges of treating hematological and solid cancer using CAR-T technology as well as its constraints and engineering approaches. We summarize other immune cells that have been using CAR technology, such as natural killer (NK), macrophages (M), and dendritic cells (DC). We conclude that CAR-T cells have the potential to treat not only cancer but other chronic diseases.",

author = "Uscanga-Palomeque, {Ashanti Concepci{\'o}n} and Ch{\'a}vez-Escamilla, {Ana Karina} and Alvizo-B{\'a}ez, {Cynthia Aracely} and Santiago Saavedra-Alonso and Terrazas-Armend{\'a}riz, {Luis Daniel} and Tamez-Guerra, {Reyes S.} and Cristina Rodr{\'i}guez-Padilla and Alcocer-Gonz{\'a}lez, {Juan Manuel}",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = nov,

doi = "10.3390/ijms242115688",

language = "English",

volume = "24",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "21",

}

Uscanga-Palomeque, AC, Chávez-Escamilla, AK, Alvizo-Báez, CA, Saavedra-Alonso, S, Terrazas-Armendáriz, LD, Tamez-Guerra, RS, Rodríguez-Padilla, C & Alcocer-González, JM 2023, 'CAR-T Cell Therapy: From the Shop to Cancer Therapy', International Journal of Molecular Sciences, vol. 24, no. 21, 15688. https://doi.org/10.3390/ijms242115688, https://doi.org/10.3390/ijms242115688

TY - JOUR

T1 - CAR-T Cell Therapy

T2 - From the Shop to Cancer Therapy

AU - Uscanga-Palomeque, Ashanti Concepción

AU - Chávez-Escamilla, Ana Karina

AU - Alvizo-Báez, Cynthia Aracely

AU - Saavedra-Alonso, Santiago

AU - Terrazas-Armendáriz, Luis Daniel

AU - Tamez-Guerra, Reyes S.

AU - Rodríguez-Padilla, Cristina

AU - Alcocer-González, Juan Manuel

PY - 2023/11

Y1 - 2023/11

N2 - Cancer is a worldwide health problem. Nevertheless, new technologies in the immunotherapy field have emerged. Chimeric antigen receptor (CAR) technology is a novel biological form to treat cancer; CAR-T cell genetic engineering has positively revolutionized cancer immunotherapy. In this paper, we review the latest developments in CAR-T in cancer treatment. We present the structure of the different generations and variants of CAR-T cells including TRUCK (T cells redirected for universal cytokine killing. We explain the approaches of the CAR-T cells manufactured ex vivo and in vivo. Moreover, we describe the limitations and areas of opportunity for this immunotherapy and the current challenges of treating hematological and solid cancer using CAR-T technology as well as its constraints and engineering approaches. We summarize other immune cells that have been using CAR technology, such as natural killer (NK), macrophages (M), and dendritic cells (DC). We conclude that CAR-T cells have the potential to treat not only cancer but other chronic diseases.

AB - Cancer is a worldwide health problem. Nevertheless, new technologies in the immunotherapy field have emerged. Chimeric antigen receptor (CAR) technology is a novel biological form to treat cancer; CAR-T cell genetic engineering has positively revolutionized cancer immunotherapy. In this paper, we review the latest developments in CAR-T in cancer treatment. We present the structure of the different generations and variants of CAR-T cells including TRUCK (T cells redirected for universal cytokine killing. We explain the approaches of the CAR-T cells manufactured ex vivo and in vivo. Moreover, we describe the limitations and areas of opportunity for this immunotherapy and the current challenges of treating hematological and solid cancer using CAR-T technology as well as its constraints and engineering approaches. We summarize other immune cells that have been using CAR technology, such as natural killer (NK), macrophages (M), and dendritic cells (DC). We conclude that CAR-T cells have the potential to treat not only cancer but other chronic diseases.

UR - http://www.scopus.com/inward/record.url?scp=85176308240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85176308240&partnerID=8YFLogxK

U2 - 10.3390/ijms242115688

DO - 10.3390/ijms242115688

M3 - Review article

C2 - 37958672

SN - 1661-6596

VL - 24

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 21

M1 - 15688

ER -

CAR-T Cell Therapy: From the Shop to Cancer Therapy

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this